Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Genes|September 28, 2021
Multi-Dimensional Scaling Analysis of Key Regulatory Genes in Prostate Cancer Using the TCGA DatabaseLaura Boldrini, Pinuccia Faviana, Luca Galli, et al.
Tumori|June 14, 2018
A case of a patient with severe renal failure on hemodialysis treated with vismodegib for relapsing basal cell carcinomaAndrea Sbrana, Andrea Antonuzzo, Luca Galli, et al.
Future Oncology (London, England)|December 25, 2019
Dedifferentiated liposarcoma: when eribulin can make the differenceAndrea Sbrana, Federico Paolieri, Francesco Bloise, et al.
Immunotherapy|March 28, 2025
Incidence and impact of immune combination therapies adverse events in advanced renal cell carcinoma patientsMartina Catalano, Giulia Venturi, Alessia Salfi, et al.
Critical Reviews in Oncology/Hematology|October 7, 2025
Adjuvant immunotherapy in high-risk renal cell carcinoma: Indications, limitations, and perspectives. A consensus statement from the GIOTTO uro-oncology groupGiandomenico Roviello, Federico Paolieri, Martina Catalano, et al.
Biomedical Reports|March 20, 2020
Clinical and economic effect of administration of red blood product transfusions in an outpatient supportive care cancer serviceAndrea Sbrana, Federico Paolieri, Francesco Bloise, et al.
Journal of Geriatric Oncology|November 2, 2019
Effectiveness of Multi-Prognostic Index in older patients with advanced malignancies treated with immunotherapyAndrea Sbrana, Rachele Antognoli, Giuseppe Pasqualetti, et al.
Cancer Chemotherapy and Pharmacology|September 18, 2020
CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abirateroneStefania Crucitta, Marzia Del Re, Federico Paolieri, et al.
Anticancer Research|August 1, 2018
Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian ExperienceAndrea Sbrana, Elisa Biasco, Federico Paolieri, et al.
Therapeutic Advances in Urology|January 20, 2026
Real-world use of enfortumab vedotin in metastatic urothelial carcinoma: efficacy, safety, and risk stratificationMartina Catalano, Sara Bartoli, Alessia Salfi, et al.
Pageof 3